First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trialLin Shen, Lin Xie, Yusheng Wang et al.|Nature Medicine|2025Cited by 89
A phase 1/2 study of LM-302, an anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate in patients with advanced gastric/gastroesophageal junction cancer.Chunmei Bai, Jin Li, Junli Xue et al.|Journal of Clinical Oncology|2024Cited by 16
Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trialLin Shen, Lin Xie, Yanqiao Zhang et al.|Nature Medicine|2025Cited by 2